1. Home
  2. SCZM vs ABUS Comparison

SCZM vs ABUS Comparison

Compare SCZM & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

SCZM

Santacruz Silver Mining Ltd. Common Shares

N/A

Current Price

$9.09

Market Cap

1.2B

Sector

N/A

ML Signal

N/A

Logo Arbutus Biopharma Corporation

ABUS

Arbutus Biopharma Corporation

HOLD

Current Price

$4.61

Market Cap

929.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SCZM
ABUS
Founded
N/A
2005
Country
Canada
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
929.6M
IPO Year
N/A
2008

Fundamental Metrics

Financial Performance
Metric
SCZM
ABUS
Price
$9.09
$4.61
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
1
Target Price
$12.00
$5.00
AVG Volume (30 Days)
459.8K
1.9M
Earning Date
05-29-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
55.26
EPS
N/A
N/A
Revenue
N/A
$14,083,000.00
Revenue This Year
$79.38
N/A
Revenue Next Year
N/A
$783.24
P/E Ratio
$14.27
N/A
Revenue Growth
N/A
128.21
52 Week Low
$6.90
$3.04
52 Week High
$17.65
$5.10

Technical Indicators

Market Signals
Indicator
SCZM
ABUS
Relative Strength Index (RSI) 52.03 55.64
Support Level $7.17 $4.19
Resistance Level $12.74 $4.64
Average True Range (ATR) 0.64 0.19
MACD 0.27 0.03
Stochastic Oscillator 68.07 76.61

Price Performance

Historical Comparison
SCZM
ABUS

About SCZM Santacruz Silver Mining Ltd. Common Shares

Santacruz Silver Mining Ltd is engaged in the operation, acquisition, exploration, and development of mineral properties in Latin America, with a primary focus on silver and zinc, including lead and copper. The company earns the majority of its revenue from Zinc and Silver. The company's reportable operating segments are the Bolivar mine and processing plant, the Porco mine and processing plant, the Caballo Blanco Group, San Lucas, Zimapan, and Corporate and Other activities. Key revenue is generated from Zimapan.

About ABUS Arbutus Biopharma Corporation

Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.

Share on Social Networks: